SignatureFD
MLYS icon

SignatureFD’s Mineralys Therapeutics MLYS Stock Holding History

SignatureFD’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$4.22K Buy
168
+51
+44% +$1.39K ﹤0.01% 2993
2026
Q2 		$3.16K Buy
+117
New +$3.21K ﹤0.01% 3011
2025
Q2 		– Sell
-22
Closed -$349 – 3362
2025
Q1 		$349 Buy
+22
New +$253 ﹤0.01% 3207

Other funds holding MLYS

Andera Partners
Andera Partners Paris $176M AUM 1.8% 1-Year Est. Return
TGY2IT
Timothy G. Youngquist 2020 Irrevocable Trust Fort Myers, Florida $530M AUM 95.29% 1-Year Est. Return
Hennion & Walsh Asset Management
Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return
KBC Group
KBC Group Brussels, Belgium $47.9B AUM 37.61% 1-Year Est. Return
FNY Investment Advisers
FNY Investment Advisers New York $402M AUM 85.9% 1-Year Est. Return
Nisa Investment Advisors
Nisa Investment Advisors St. Louis, Missouri $34.7B AUM 25.93% 1-Year Est. Return
Sterling Capital Management
Sterling Capital Management Charlotte, North Carolina $4.92B AUM 24.73% 1-Year Est. Return
GAMMA Investing
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
Versant Capital Management
Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return
MassMutual Private Wealth & Trust
MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return

SignatureFD's MLYS Position: Q3 2026 in Review

SignatureFD increased its Mineralys Therapeutics (MLYS) stake by 44% in Q3 2026, buying an estimated $1.39K and bringing the position to 168 shares worth $4.22K. The position accounts for ﹤0.01% of the portfolio, ranked #2993.

SignatureFD first reported a position in MLYS in Q1 2025 and has held it in 3 quarters since. 18 funds tracked by Wall St. Rank hold MLYS as of Q3 2026.

  • SignatureFD held 168 shares of Mineralys Therapeutics worth $4.22K as of Q3 2026.
  • SignatureFD bought 51 Mineralys Therapeutics shares in Q3 2026, an estimated $1.39K.
  • Mineralys Therapeutics made up ﹤0.01% of SignatureFD's portfolio in Q3 2026, its #2993 holding.
  • SignatureFD first reported a position in Mineralys Therapeutics in Q1 2025 and has held it in 3 quarters since.
  • 18 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q3 2026.

Based on SignatureFD's 13F filing for Q3 2026, filed 23 Oct 2026.